ALIBABA-CLOUD
17.9.2020 04:46:11 CEST | Business Wire | Press release
Alibaba Cloud, the digital technologies and intelligence backbone of Alibaba Group, today unveiled a series of innovative products at its 12th annual Apsara Conference, highlighting the technology pioneer’s commitment in helping people adapt to the more digitized world and accelerate customers’ digital transformation during and after the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916006004/en/
A highlight is Alibaba Cloud’s first cloud computer , a palm-sized personal computer which, despite being just about 60 grams and as light as an egg, offers high-performance computing, thanks to robust back-end cloud resources. By simply connecting the cloud computer with a normal computer screen, a user can access almost unlimited computing resources anytime, anywhere, while paying on a subscription model or for the actual cloud consumption.
“We hope our cloud computer can help people access resilient computing power whenever they need to, so they can conduct complex tasks which usually require sophisticated and powerful PCs, such as video editing, animation rendering, software development, and online customer services, with a tiny personal computer at hand now,” said Jeff Zhang, President of Alibaba Cloud Intelligence . “As working from home becomes the new normal during and after the pandemic, we believe our innovation can also help users more easily enjoy the benefits of cloud computing anytime, anywhere, in a cost-effective yet secure way.”
With robust computing power, the cloud computer can reduce the rendering time of one frame high-resolution animation from 90 minutes using a traditional PC, down to only 10 minutes. In addition, the cloud computer’s system upgrades are conducted online, saving a big chunk of the normally heavy cost of PC machine upgrades and maintenance in traditional office settings. Through Alibaba Cloud's self-developed app-streaming protocol, which is designed for synergy between the cloud and the device, users can also purchase and access licensed apps and programs such Linux and Windows as well as various office applications. All user data will be stored on cloud for datacenter-grade security and protection measures. Available initially for enterprise customers, the cloud computers will be also available for purchase by individual consumers in the near future.
Alibaba Cloud also unveiled its autonomous logistics robot for last-mile deliveries. Developed by the Alibaba DAMO Academy, the global research initiative by Alibaba Group, the delivery robot can carry 50 packages at one time and cover 62 miles (or 100 kilometres) on a single charge. It is estimated the mobile robot should be able to deliver as many as 500 packages a day to one designated community or campus, meeting the rising demand for speedy last-mile delivery in China. Online shopping is booming there, with 200 million packages delivered daily and expectations that will rise to 1 billion packages per day in the coming years.
“We are expecting a rapid spike of delivery demands brought by the thriving New Retail and local services businesses in the increasingly digitalized world,” added Zhang. “To meet the strong delivery demand for our internal business growth and for the larger society, we have been investing in smart logistics, including logistics robots, for years. We are glad to launch our latest mobile delivery robot, which will support Cainiao, Alibaba’s logistics platform, to serve communities, campuses and business parks in China. “
“Moving ahead, we aim to support the delivery needs of our local services businesses and leverage our technologies for other types of service robots, such as service robots in the airport and tourism guide robots in scenic spots.”
Supported with reinforced learning technologies, the intelligent robot can schedule its route even in a crowded environment. With proprietary, high-definition positioning technology, the robot can operate even where there’s weak or no GPS signal. Leveraging a self-developed heterogeneous computing platform, 3D Point Cloud Semantic Segmentation (PCSS) technology and deep learning, the robot can also identify obstacles and predict the intended movement of passengers and vehicles a few seconds ahead of time to enhance safety.
Consumers can use either the Cainiao or Taobao mobile apps to select a preferred timeslot during the day for delivery. The robot then arrives at the designated destination, where users retrieve their packages simply by entering a passcode they receive in the app, once the robot arrives.
A slew of cloud-native products were unveiled during the Conference:
- Cloud Lakehouse : This is the next-generation big data architecture which can deliver significant data-based values and intelligence through cross-platform computing, intelligent cache, hot/cold data separation, storage improvement and performance acceleration.
- Sandboxed-Container 2.0 : Alibaba’s cloud-native container service for Kubernetes supports clusters that provide sandboxed container runtimes. The new Sandboxed-Container 2.0 enables customers to run applications in lightweight sandboxed environments with faster speeds and reduced cost of runtime resources.
- PAI-DSW 2.0 : The latest Cloud-native Machine-learning Interactive Development Platform by Alibaba. It aims to provide an optimal environment for developers that is easy to use, compatible with community plug-ins and supports multi-development environments like JupyterLab, WebIDE and Terminal.
- Lindorm: The cloud-native multi-model database that is used to support the Alibaba Group ecosystem, is introduced to benefit the wider Alibaba Cloud ecosystem. Lindorm is a cloud-native database, with affordable storage and flexible processing characteristics. It is designed for applications with massive processing requirements for a mixture of unstructured, semi-structured, and structured data.
The conference, named “Leap Into the Future of Digital Intelligence,” was entirely hosted online for the first time, with over 100 virtual forums on topics ranging from cloud computing, IoT to machine learning and industrial AI solutions.
For more information about the Apsara Conference, please visit the website: https://www.alibabacloud.com/apsara-conference-2020
About Alibaba Cloud
Established in 2009, Alibaba Cloud (alibabacloud.com), the digital technology and intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916006004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
